Can The Research That Drives Health Reform Be Reformed?
Health services research, the basis of health reform, needs to focus on real-world impact and communicate its benefits says Aaron Carroll, the new president of AcademyHealth.
Cincinnati Children’s Is A Unicorn, But It Should Be A Role Model
Cincinnati Children’s is a patient safety unicorn, a place where achieving zero patient harm is a genuine cornerstone of the corporate culture.
Hospitals Merge For Power, While ‘Price Transparency’ Fantasy Persists
A new study highlights a pervasive government failure to prevent hospital mergers that give providers excess pricing power. Price transparency is unlikely to compensate.
Shared Decision Surprises: Ineffectual AI And A ‘Flea Market’ Ending
Researchers examining how patients make medical decisions are turning up some unexpected results.
The Coalition For Health AI Is A ‘Goo-Goo,’ Not Yet A Revolutionary
The Coalition for Health AI wants to be the “curator of best practices of AI in health,” but it’s unclear if that will involve enabling true patient empowerment.
AI Chatbots Speak No Evil About Questionable Doctors, Hospitals
When it comes to warning the public about potentially harmful health care, ChatGPT and Gemini clam up, even if the misdeeds were widely publicized..
Will Wearable Health Device Data Bring Woe Or Wealth To Providers?
Researchers applied game theory to find out whether incorporating patient-generated health data into the clinical work flow will boost or bring down providers’ profits.
Overuse Of Health Care ‘Crisis’ Label Blocks Facing Policy Reality
The phrase “health care crisis” long ago evolved into an incantation, but even well-intentioned crisis-mongering can hurt the crucial task of facing political reality.
Austin’s Post-Op Infection Highlights Lag In CDC’s Overall Prevention Effort
The effectiveness of the effort to reduce healthcare-associated infections is obscured as much as revealed in the latest data from the CDC.
Sorry, Santa: AbbVie Shows ‘Naughty’ Can Be Profitably Nice (For Some)
AbbVie’s “patent thicket” strategy and aggressive drug pricing tactics have made it a prominent example of pharma finagling. But the company isn’t the only beneficiary.